Padcev and Keytruda Combination Improves Bladder Cancer Survival without Adversely Impacting Quality of Life
Padcev and Keytruda have been found to enhance survival rates and slow disease progression in patients with bladder cancer, without causing negative effects on pain, functioning, or quality of life. A recent study, known as the EV-302 trial, involved 886 patients with locally advanced or metastatic urothelial cancer who were treated with either Padcev and Keytruda or platinum-based chemotherapy.
The results of the study revealed that the combination of Padcev and Keytruda led to improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. Patients receiving Padcev and Keytruda also experienced a longer period before their pain progressed, indicating a positive impact on their quality of life.
The trial data presented at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting by Dr. Shilpa Gupta showed that the combination of Padcev and Keytruda nearly doubled PFS and OS in patients with locally advanced or metastatic urothelial cancer. The study also demonstrated that Padcev and Keytruda did not negatively affect patients’ quality of life, pain levels, or functioning.
Overall, the study findings suggest that the combination of Padcev and Keytruda is a promising treatment option for patients with bladder cancer, offering improved survival outcomes without compromising quality of life.
For more updates on cancer research and education, be sure to subscribe to CURE®’s newsletters.
